The neoadjuvant study (Clinicaltrials.gov ID: NCT05710406) is a phase II/III study assessing whether combining the RAF inhibitor encorafenib with the EGFR inhibitor cetuximab improves the disease-free survival in resected, BRAF V600E-mutant, high-risk, stage II or III colon cancer patients post-standard adjuvant therapy. This evidence concerns the gene BRAF and malignant colon neoplasm.